clinical trial · NCT07168200
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd·phase3·recruiting·n = 720
Advanced Cervical CancerSHR-1316 InjectionCisplatin InjectionCarboplatin InjectionPaclitaxel InjectionSHR-1316 Placebo Injection
brief summary
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
started
Oct 17, 2025
primary completion
Apr 1, 2028
completion
Dec 1, 2028
last updated
Apr 15, 2026
official title
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol